Pharma/Biotech stocks News; BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) To Present at Cancer Immunotherapy Conference

LINCOLNSHIRE, Ill. - October 3, 2011 (Investorideas.com newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) will present at the Cancer Immunotherapy: A Long Awaited Reality conference taking place on October 6, 2011, at the New York Academy of Medicine in New York. The single-day conference event unites key opinion leaders, industry executives, and other stakeholders to engage in discussions, exchange information, and highlight opportunities in the field of cancer immunotherapy.

Stephen M. Simes, BioSante's president & chief executive officer, will speak at 1:45 pm EDT, and will provide an overview of BioSante's portfolio of cancer vaccines currently in multiple Phase II clinical trials.
The conference will be hosted by MD Becker Partners and sponsored by JMP Securities, Thompson Hine, Roth Capital Partners and Cantor Fitzgerald. There will be a corresponding live webcast of the presentations, which can be accessed by visiting www.regonline.com/mdbpartners. A replay will be available for 30 days.
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is seeking opportunities for its other technologies. Additional information is available online at: www.biosantepharma.com.
About MD Becker Partners
MD Becker Partners LLC is a boutique management and strategy consulting firm focusing on both public and private companies in the life science industry. As a strategic advisor and partner, the firm provides a full range of services to help clients increase visibility, unlock stakeholder value and access resources to grow their business. To accomplish this, MD Becker Partners integrates relations, strategy, and operational capabilities and applies them to carefully conceived and expertly enacted tactics. For more information visit www.mdbpartners.com.
Contact:
BioSante Pharmaceuticals
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953
tswanson@troutgroup.com
or
For Media:
Harris D. McKinney, Inc.
Alan Zachary, 312-506-5220
azachary@harrisdmckinney.com
BioSante Pharmaceuticals, Inc: (NASDAQ: BPAX) is a featured showcase biotech/pharma stock on Investorideas.com
Request news, updates and trading alerts on BPAX and other showcase stocks http://www.investorideas.com/Resources/Newsletter.asp
Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing, covering leading industry sectors including biotech and pharma stocks.
Disclaimer: The following news/content is paid for as part of the BPAX showcase program (two thousand per month) Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp  
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp  
Source: Investorideas.com, BioSante, Investorideas.com
800 665 0411 cvanzant@investorideas.com